Significant Genotypic and Phenotypic Analytic Capabilities Added in New Release
Oracle Health Sciences today announced the availability of Oracle Health Sciences Translational Research Center 3.0, a platform that enables secondary use of electronic health records and omics data to help accelerate biomarker identification for drug discovery, clinical development and translational medicine.
Clinical researchers are focused on advancing the secondary use of medical data across clinical and research organizations to unlock the true potential of personalized medicine. To support this goal, the latest release of Oracle Health Sciences Translational Research Center features expanded omics and clinical data models, new user interfaces and workflows for patient stratification and reporting, advanced analytical capabilities that facilitate the discovery of driver mutations, and enhanced role-based data access security, ultimately supporting accelerated insight needed to advance personalized medicine.
Oracle approximately doubled the size of the omics and clinical data models in the newest release to lay a foundation for expanded insight and discovery. The clinical data model now includes more than 70 major tables – up from approximately 35 - as well as many new attributes, such as medical encounters, treatment outcomes and patient’s family medical histories.
Highlights of the release:
“Through our Moon Shots program, MD Anderson is driving advances in personalized medicine that will lead to more targeted therapies and ultimately improve cancer care outcomes for our patients,” said Dr. John Frenzel, chief medical information officer, University of Texas MD Anderson. “The ability to integrate and analyze this complex genotypic and phenotypic data is critical in achieving this goal. When we purchased Oracle Health Sciences Translational Research Center in November 2012, we expected it to be a key component of our Moon Shots architecture. The new capabilities added to this version of the platform help to ensure that it will continue to meet our needs as genomic technologies in clinical care evolve.”
“The future of personalized medicine rests on our collective ability to rapidly advance secondary use of health information and glean new insight from it. Oracle Health Sciences Translational Research Center is purpose-built for this objective,” said Jonathan Sheldon, PhD, Global Vice President, Oracle Health Sciences. “The latest version of the solution supports many new genotypic and phenotypic analytic capabilities that will speed biomarker discovery and subsequent application in both clinical trials and clinical care settings.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.